Intravitreal low-dosage bevacizumab for retinopathy of prematurity.
about
Insulin-like growth factor-1 and anti-vascular endothelial growth factor in retinopathy of prematurity: has the time come?Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity.Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective AnalysisA Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity.Serial evaluation of retinal vascular changes in infants treated with intravitreal bevacizumab for aggressive posterior retinopathy of prematurity in zone I.Role of VEGF Inhibition in the Treatment of Retinopathy of Prematurity.Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison.Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.Quantitative analyses of retinal vascular area and density after different methods to reduce VEGF in a rat model of retinopathy of prematurity.Effect of two different doses of intravitreal bevacizumab with temporal retina-sparing laser photocoagulation for retinopathy of prematurity.Efficacy of Intravitreal Bevacizumab for the Treatment of Zone I Type 1 Retinopathy of Prematurity.Ultra-low dose of intravitreal bevacizumab in retinopathy of prematurity.Higher prolactin and vasoinhibin serum levels associated with incidence and progression of retinopathy of prematurity.Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits.Retinopathy of prematurity: preferred practice patterns among pediatric ophthalmologists.
P2860
Q34339456-01D4ACB4-36E9-4BA4-84F9-F6EF60127B73Q35207113-777C466B-0C8C-4100-8A2E-C93B2A8AC645Q35553854-BA0910D2-6FDA-4A1A-B05B-2A29D38B3D57Q35665701-55AAAC9F-D066-48E0-B6F6-72652A48BB75Q35846321-A94DA4AE-145F-4FE7-968E-1ED7F9579AC7Q35950878-9856E9FE-7F3C-450B-88AD-D8CC3962BD79Q35969307-29A6AD0B-725D-4F8F-9A52-D60DB0A25025Q36078573-D0549A1D-374E-483D-9504-399829058D6AQ37561227-5A907454-A23C-4282-95FF-A8084D849E89Q49247591-EEEB80C6-A95D-41D9-946C-3D0A0FE0C093Q49362470-F653ABF6-EA73-4F2A-A1FC-30E8624C4267Q49501136-4F7A8B54-BF95-4226-AC1A-360039431458Q50122404-16417EFD-3665-4048-9104-97822BB9D958Q51697739-1537ECD0-5242-48C3-BB85-EAF41C9FCAC8Q55005735-1DE7A533-C311-4C5A-B845-F96D8DA7E2DA
P2860
Intravitreal low-dosage bevacizumab for retinopathy of prematurity.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Intravitreal low-dosage bevacizumab for retinopathy of prematurity.
@en
Intravitreal low-dosage bevacizumab for retinopathy of prematurity.
@nl
type
label
Intravitreal low-dosage bevacizumab for retinopathy of prematurity.
@en
Intravitreal low-dosage bevacizumab for retinopathy of prematurity.
@nl
prefLabel
Intravitreal low-dosage bevacizumab for retinopathy of prematurity.
@en
Intravitreal low-dosage bevacizumab for retinopathy of prematurity.
@nl
P2093
P2860
P356
P1433
P1476
Intravitreal low-dosage bevacizumab for retinopathy of prematurity.
@en
P2093
Björn C Harder
Frank C Schlichtenbrede
Stefan von Baltz
P2860
P304
P356
10.1111/AOS.12266
P50
P577
2013-09-11T00:00:00Z